NEW YORK (GenomeWeb News) – Citi Research analyst Amit Bhalla has increased his price target on Agilent Technologies' stock from $43 to $50 and has increased earnings-per-share estimates for the firm.

In a research note published last night Bhalla said that Citi has upped its FY 2013 EPS estimate for Agilent to $3.04 from $3.00 and FY 2014 EPS estimate to $3.40 from $3.29. He also said he believes Agilent will produce organic revenue growth of 4 percent to 5 percent for 2014 and 2015, rather than the 3 percent originally modeled by the bank.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.